Eight HBsAg, HBeAg, DNA-p, HBV-DNA-positive patients with biopsy-proven chronic hepatitis were treated with human lymphoblastoid interferon (Wellferon) given for 28 consecutive days at a dosage ranging from 2.5 to 7.5 MU/m2 i.m.; 10 patieints were used as controls. Our results suggest that certain chronic carriers may respond to the treatment with this agent. In fact, the treated patients showed a permanent inhibition of HBV replication sooner and in higher percentage with respect to untreated patients (37.5% vs 20%). IFN administration does not induce any important change in the immunoregulatory wetwork, but is able to increase significantly the cytolytic activity of NK cells in the patients who respond to the therapy with a permanent inhibition of HBV replication. © 1986 Elsevier Science Publishers, Amsterdam All rights reserved.
EFFECT OF 28 CONSECUTIVE DAYS LYMPHOBLASTOID INTERFERON (ALPHA-IFN) ADMINISTRATION ON HEPATITIS-B VIRUS RELATED CHRONIC LIVER-DISEASE / A., Franco; Barnaba, Vincenzo; Levrero, Massimo; G., Ruberti; A., Van Dyke; M. S., Bonavita; F., Balsano. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 3:2(1986), pp. S239-S243. [10.1016/s0168-8278(86)80127-1]
EFFECT OF 28 CONSECUTIVE DAYS LYMPHOBLASTOID INTERFERON (ALPHA-IFN) ADMINISTRATION ON HEPATITIS-B VIRUS RELATED CHRONIC LIVER-DISEASE
BARNABA, Vincenzo;LEVRERO, Massimo;
1986
Abstract
Eight HBsAg, HBeAg, DNA-p, HBV-DNA-positive patients with biopsy-proven chronic hepatitis were treated with human lymphoblastoid interferon (Wellferon) given for 28 consecutive days at a dosage ranging from 2.5 to 7.5 MU/m2 i.m.; 10 patieints were used as controls. Our results suggest that certain chronic carriers may respond to the treatment with this agent. In fact, the treated patients showed a permanent inhibition of HBV replication sooner and in higher percentage with respect to untreated patients (37.5% vs 20%). IFN administration does not induce any important change in the immunoregulatory wetwork, but is able to increase significantly the cytolytic activity of NK cells in the patients who respond to the therapy with a permanent inhibition of HBV replication. © 1986 Elsevier Science Publishers, Amsterdam All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
